Actively Recruiting
Association Between Human Immunodeficiency Virus (HIV) Infection and Male Hypogonadism
Led by National Taiwan University Hospital · Updated on 2021-03-03
1200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the prevalence of hypogonadism, a condition involving low testosterone, among HIV-infected men who have sex with men (MSM). The study compares this group with age-matched MSM who are not infected with HIV. It also aims to identify risk factors for male hypogonadism such as age, duration of HIV infection, other health conditions, body mass index, and antiretroviral therapy use. The relationship between testosterone levels and aspects like sexual function, energy, exercise ability, mood, and bone density will be explored. This observational, cross-sectional study includes two groups: HIV-infected MSM and HIV non-infected MSM. Participants will have their serum total and free testosterone levels measured as a diagnostic test. The main outcomes measured during the study period from 2021 to 2030 are symptoms of androgen deficiency and serum free testosterone levels. Participants will be assessed for symptoms related to low androgen and have blood tests for testosterone. The study will also correlate testosterone levels with sexual health, vitality, exercise capacity, mood, and bone mineral density. The study is conducted by the National Taiwan University Hospital and allows healthy volunteers who meet the criteria to participate. The total duration extends through 2030, with ongoing data collection and analysis.
CONDITIONS
Brief Title
Association Between Human Immunodeficiency Virus (HIV) Infection and Male Hypogonadism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- HIV-infected men who have sex with men
- HIV non-infected men
You will not qualify if you...
- Use of testosterone supplement or anabolic steroid in the past one year
- History of pituitary, adrenal, or gonad diseases
- History of pituitary surgery or radiation therapy
- History of systemic chemotherapy
- Active opportunistic infection under treatment
- Cancer
- Severe hepatic, renal, or cardiac impairment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single time point
Participants undergo blood tests to measure serum total and free testosterone levels along with assessments of sexual function, vitality, exercise capacity, mood, and bone mineral density.
1 visit (in-person)
Duration - Up to 9 years until 2030
Participants are observed over time to assess symptoms of androgen deficiency and changes in serum testosterone levels.
Periodic visits depending on study schedule
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, 100
Actively Recruiting
Research Team
S
Shyang-Rong Shih, Ph.D.
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here